Article
Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
Blood - 26 Feb 2015
Appelmann Iris, Rillahan Cory D, de Stanchina Elisa, Carbonetti Gregory, Chen Chong, Lowe Scott W, Sherr Charles J
Abstract excerpt
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is initiated and driven by the oncogenic fusion protein BCR-ABL, a constitutively active tyrosine kinase. Despite major advances in the treatment of this highly aggressive disease with potent inhibitors of the BCR-ABL kinase such as dasatinib, patients in remission frequently relapse due to persistent minimal residual disease possibly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.